Syntara Ltd Trading Halt Pending iRBD Study Results
Key points
- Trading halt requested by Syntara Ltd pending announcement of iRBD Parkinson's study results
- Halt will remain until preliminary results are released or trading resumes on 6 July 2026
- Company confirms no undisclosed reasons against granting the halt
Full summary
Syntara Limited (ASX: SNT) has requested a trading halt on its securities to prevent trading until the announcement of preliminary results from the iRBD Parkinson's disease study of SNT-4728. The halt will remain in effect until the earlier of the release of the announcement or the commencement of trading on 6 July 2026. The company confirms it is not aware of any reasons why the trading halt should not be granted.
Summary generated by a large language model. Please interpret with care.